A systems approach to enhance clinical research and medicines development
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 1
Abstract
The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clinical trial system is inefficient and flawed. Most challenges are worsened by the inability of the stakeholders to work collaboratively. Over the last decade, many cooperative efforts to transform clinical research have been launched, but a systemic solution has not been envisioned. A systems approach, including the application of systems engineering principles, has been used in other sectors and proposed for use in healthcare and medicines development. Clinical research, when looked at in systems terms, can be defined as an open system involving patients, investigators and associated staff, regulators, sponsors and stakeholders interconnected through a series of processes to bring effective and safe medicines into the market. ACRES is a global nonprofit organization with a mission of creating a multi-sector alliance of individuals and institutions collaborating on building a shared global system for clinical research excellence. A fundamental element of the ACRES system includes a global network of high-performing research sites interconnected through a shared information technology platform, with standardized policies and operational procedures and a robust, secure database to support performance, quality and safety. Five core initiatives address the larger mission and are currently ongoing. Deliverables will roll out over 2015–2018. Positive reception to the concept, vision and goals among critical stakeholders, and a steady influx of strategic allies willing to work collaboratively demonstrates the strong pull exerted by the vision of a global system. However, due to the undertakings’ scope and complexity, challenges remain. Recognition that effective shared collaboration is the best long-term option among stakeholders and the general public constitutes a powerful incentive for ACRES contributors and strategic allies to keep working and make it happen.
Authors and Affiliations
Honorio Silva, Greg Koski, Matthew Whalen, Mary Tobin, Beat Widler, Al O. Pacino II and Brian Edwards
Keywords
Related Articles
- EP ID EP679261
- DOI -
- Views 152
- Downloads 0
Role of the P2Y6 receptor of UDP in the modulation of murine dendritic cell functions and Th1 polarisation of the immune response
Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y6 receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y6 receptor in the adaptive immune respons...
LifeTrain: Driving lifelong learning for biomedical professionals
This article describes LifeTrain — the European common framework for continuing professional development in the biomedical sciences. An important goal of LifeTrain is to support biomedical professionals to work collabora...
Investigative safety strategies to improve success in drug development
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are t...
Brazil is gaining its momentum in pharmaceutical development
Brazil is one of the world’s largest economies and pharmaceutical markets, having the Brazilian government as an important purchaser. There are strong local companies that have grown sustainably after the introduction of...
Philanthropies as partners for drug development in public–private partnerships
Disease-focused philanthropic organizations play an increasing role in the strategy and conduct of biomedical research, with many focusing on drug development for specific diseases and patient populations. More and more...